Valeda is a Platform Utilizing Photobiomodulation to Deliver Specific Wavelengths to the Eye

The Valeda Light Delivery System is a breakthrough medical device designed for physicians dedicated to advancing the treatment of degenerative eye conditions.

Valeda delivers a non-invasive, multiwavelength, light-based therapy that utilizes photobiomodulation (PBM) to treat dry age-related macular degeneration (AMD) patients to improve vision.

Valeda’s targeted treatment addresses mitochondrial dysfunction in the retina, a key component of dry age-related macular degeneration (AMD) , to improve visual acuity and enhance patient outcomes.

It’s Time for Patients to See Their Future

Valeda integrates seamlessly into clinical practice. Backed by extensive research and designed to optimize therapeutic benefits, Valeda is an essential addition for managing patients with dry age-related macular degeneration (AMD).

Valeda is the first photobiomodulation (PBM) device designed specifically for ophthalmic applications.

Valeda is the only photobiomodulation (PBM) device to be granted FDA de Novo authorization for medical claims associated with the treatment of dry age-related macular degeneration (AMD).

Treatments are delivered in a series of 9 sessions per eye over 3 – 5 weeks.

The Valeda Light Delivery System is intended to provide improved visual acuity in patients with best corrected visual acuity of 20/32 through 20/70 and who have dry age-related macular degeneration (AMD) characterized by:

  • The presence of at least 3 medium drusen {> 63 μm and ≤ 125 μm in diameter), or large drusen {> 125μm in diameter), or non-central geographic atrophy, AND
  • The absence of neovascular maculopathy or center-involving geographic atrophy

After about two years, the Valeda Light Delivery System treatment provides improved mean visual acuity of approximately one line of visual acuity (ETDRS) compared to those not receiving the treatment.

As a precaution, patients have not been tested and should not be treated with Valeda if they have any known photosensitivity to yellow light, red light or near-infrared radiation (NIR), or if they have a history of light activated central nervous system disorders (e.g. epilepsy, migraine). In addition, patients should not receive treatment within 30 days of using photosensitizing agents (e.g. topicals, injectables) that are affected by 590, 660, and/or 850 nm light before consulting with their physician.

Refer to the Valeda Light Delivery System User Manual for full Important Safety Information.

Now’s the Time to Talk

Request time with one of our representatives to learn more about Valeda.

Contact Us
Valeda